Logo

BMRA

Biomerica, Inc.

BMRA

Biomerica, Inc. • NASDAQ
$2.34 ▲ 0.86% (+0.02)
Market Cap $6.71 M
52w High $10.16
52w Low $2.08
Dividend Yield 0%
P/E -1.53
Volume 4.53K
Outstanding Shares 2.87M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $1.38M ▲ $1.542M ▲ $2K ▲ 0.145% ▲ $0.003 ▲ $107K ▲
Q4-2025 $749K ▼ $1.32M ▲ $-1.544M ▼ -206.142% ▼ $-0.16 ▼ $-1.46M ▼
Q3-2025 $1.119M ▼ $1.229M ▼ $-1.163M ▼ -103.932% ▼ $-0.068 ▼ $-1.111M ▼
Q2-2025 $1.636M ▼ $1.43M ▼ $-950K ▲ -58.068% ▲ $-0.056 ▲ $-993K ▲
Q1-2025 $1.807M $1.657M $-1.316M -72.828% $-0.078 $-1.271M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $3.053M ▲ $6.854M ▲ $1.699M ▼ $5.155M ▲
Q4-2025 $2.399M ▼ $5.945M ▼ $1.84M ▼ $4.105M ▼
Q3-2025 $3.058M ▲ $7.376M ▲ $1.842M ▼ $5.534M ▲
Q2-2025 $2.372M ▼ $7.274M ▼ $2.16M ▼ $5.114M ▼
Q1-2025 $2.82M $7.87M $2.524M $5.346M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $2K ▲ $-268K ▲ $-37K ▼ $920K ▲ $617K ▲ $-268K ▲
Q4-2025 $-1.544M ▼ $-661K ▲ $4K ▲ $-5K ▼ $-658K ▼ $-661K ▲
Q3-2025 $-1.163M ▼ $-1.045M ▼ $-4K ▲ $1.736M ▲ $686K ▲ $-1.045M ▼
Q2-2025 $-950K ▲ $-791K ▲ $-33K ▲ $380K ▲ $-448K ▲ $-791K ▲
Q1-2025 $-1.316M $-1.344M $-63K $63K $-1.35M $-1.344M

Revenue by Products

Product Q2-2022Q3-2022Q2-2024Q3-2024
Clinical Lab
Clinical Lab
 $0 ▲$0 ▲$0 ▲$0 ▲
Contract Manufacturing
Contract Manufacturing
 $0 ▲$0 ▲$0 ▲$0 ▲
Physicians Office
Physicians Office
 $0 ▲$0 ▲$0 ▲$0 ▲
ClinicalLabMember
ClinicalLabMember
 $0 ▲$0 ▲$0 ▲$0 ▲
ContractManufacturingMember
ContractManufacturingMember
 $0 ▲$0 ▲$0 ▲$0 ▲
OverthecounterMember
OverthecounterMember
 $0 ▲$0 ▲$0 ▲$0 ▲
PhysiciansOfficeMember
PhysiciansOfficeMember
 $0 ▲$10.00M ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Biomerica’s income statement reflects a very small, early‑stage commercial business. Revenue has stayed tiny and fairly flat over the last several years, suggesting that core products are still in the early phases of market adoption. The company has generally operated at a loss, with operating and net income consistently negative. Losses don’t appear extreme relative to the company’s scale, but they are persistent, which means the business is still in “build and invest” mode rather than a mature profit-generating phase. Any future shift will depend heavily on ramping sales of its newer diagnostic offerings and services rather than cost cutting alone.

Balance Sheet

Balance Sheet The balance sheet is lean and modest in size, as you would expect from a small medical device and diagnostics company. Total assets have stayed relatively stable, not showing big expansion, which indicates careful spending but also limited growth in physical or financial resources. Cash balances have come down from earlier levels, which narrows the company’s financial cushion. A notable positive is the absence of meaningful debt, which reduces pressure from interest payments and refinancing. Equity has been drifting lower over time due to ongoing losses, leaving a thinner buffer to absorb future setbacks and making access to outside capital more important.

Cash Flow

Cash Flow Cash flow trends underline the story of a company still investing to reach scale. Operating cash flow has been negative in most recent years, meaning the business consumes cash to fund operations rather than generating it. Free cash flow moves in line with this because capital spending is very light, so the main driver is operational performance rather than heavy investment in equipment or facilities. This pattern is typical for a small, innovation‑driven healthcare company, but it also means Biomerica’s runway is closely tied to its ability to control costs, grow revenue, and, if needed, raise additional capital over time.

Competitive Edge

Competitive Edge Biomerica occupies a specialized niche in gastrointestinal diagnostics and personalized, diagnostic‑guided therapy. Its inFoods platform for IBS and other GI conditions gives it a differentiated, clinically validated solution in an area where many patients are dissatisfied with current options. Strong patent coverage and peer‑reviewed clinical data help create a moat versus generic food sensitivity tests and less validated competitors. The recent FDA clearance for its H. pylori test and its push into contract development and manufacturing strengthen its credibility and diversify potential revenue sources. However, the company competes against much larger diagnostics players with deeper sales networks and marketing budgets, and it still has to prove it can achieve broad physician adoption, insurance reimbursement, and international scale from a small base.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Biomerica’s strategy. The inFoods technology, focused on identifying food triggers and guiding personalized diets, is a novel way to manage IBS and potentially other inflammatory or functional conditions. The AI‑enhanced Trigger Food Navigator adds a digital, patient‑engagement layer that could deepen the value of the test beyond a one‑time result. The company has secured a wide patent estate that extends the core technology to other diseases such as GERD, Crohn’s disease, and ulcerative colitis, and is exploring applications in areas like migraines and osteoarthritis. Its work on H. pylori testing and its broader diagnostic menu further highlight a strong R&D orientation. The main tension is that ambitious R&D and clinical programs are resource‑intensive, while the current financial base is relatively small, making prioritization and disciplined execution critical.

Summary

Overall, Biomerica looks like a classic high‑innovation, financially fragile small healthcare company. On one side, it has a distinctive technology platform, meaningful intellectual property, credible clinical data, and a focused niche in GI‑related personalized medicine, all of which support a compelling long‑term narrative. On the other side, revenue remains very small, profitability has not yet been achieved, cash generation is weak, and the balance sheet is thin, which heightens execution and financing risk. The company’s future will likely hinge on whether it can translate its innovations—especially inFoods IBS, follow‑on GI tests, and CDMO services—into sustained, growing commercial demand while maintaining enough financial flexibility to support ongoing development and market expansion.

NEWS

November 25, 2025 · 8:19 AM UTC

Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

Read more

November 6, 2025 · 8:19 AM UTC

Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand

Read more

October 16, 2025 · 8:19 AM UTC

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

Read more

October 15, 2025 · 9:27 AM UTC

Biomerica Reports First Quarter Fiscal 2026 Financial Results

Read more

October 8, 2025 · 8:19 AM UTC

Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

Read more